Introduction: Dentistry's Expanding Role in Sleep Medicine

Obstructive sleep apnea (OSA) affects an estimated 936 million adults globally (aged 30–69 years) with an apnea-hypopnea index (AHI) ≥ 5 events/hour, according to a 2019 analysis published in The Lancet Respiratory Medicine (Benjafield et al., 2019). Within this population, approximately 425 million have moderate-to-severe OSA (AHI ≥ 15), representing a condition with profound cardiovascular, metabolic, neurocognitive, and public safety implications. Oral appliance therapy (OAT), primarily through mandibular advancement devices (MADs), has emerged as the leading non-CPAP treatment modality, supported by a robust evidence base and endorsed by the American Academy of Sleep Medicine (AASM) as a first-line therapy for mild-to-moderate OSA and an alternative for severe OSA when CPAP is not tolerated.

This article provides a comprehensive review of dental sleep medicine and OAT, covering diagnostic pathways, MAD appliance design categories, clinical efficacy benchmarks, side effect management, the critical role of physician-dentist collaboration, and the emerging role of digital workflows and remote monitoring technology.

Obstructive Sleep Apnea: Pathophysiology and Diagnostic Framework

Pathophysiology

OSA is characterized by repetitive partial (hypopnea) or complete (apnea) collapse of the upper airway during sleep, resulting in intermittent hypoxemia, sympathetic nervous system activation, and sleep fragmentation. The primary anatomical site of collapse is the velopharyngeal region (retropalatal), followed by the oropharyngeal (retrolingual) region, and in a minority of cases, the hypopharyngeal region (Epiglottis). The collapse occurs when the negative intraluminal pressure generated during inspiration exceeds the dilator muscle tone — a balance that degrades with age, obesity, anatomical predisposition, and neuromuscular dysfunction.

OSA severity is classified by the apnea-hypopnea index (AHI):

• Mild: 5 ≤ AHI < 15 events/hour
• Moderate: 15 ≤ AHI < 30 events/hour
• Severe: AHI ≥ 30 events/hour

Diagnostic Pathways

The gold standard for OSA diagnosis remains in-laboratory polysomnography (PSG, Type I), which records EEG, EOG, EMG, airflow, respiratory effort, oxygen saturation, and ECG simultaneously. However, the rise of home sleep apnea testing (HSAT, Type III) has dramatically increased access to diagnosis. A 2022 comparative study in Chest found that Type III HSAT demonstrated 92% sensitivity and 77% specificity for AHI ≥ 15 when interpreted by board-certified sleep physicians, with concordance within 5 events/hour of PSG in 78% of cases (Rosen et al., 2022).

HSAT devices typically measure airflow via nasal cannula, respiratory effort via inductive plethysmography, and oxygen saturation via pulse oximetry. They do not measure sleep versus wake time (no EEG), meaning that AHI is calculated based on total recording time rather than total sleep time, which can underestimate true AHI by 10–20% in patients with poor sleep efficiency.

The dentist's role in the diagnostic pathway is not to diagnose OSA independently but to recognize signs and symptoms, screen using validated questionnaires (STOP-BANG, Epworth Sleepiness Scale), and refer to a board-certified sleep physician for diagnosis. The physician retains responsibility for the diagnosis, treatment plan, and ongoing disease management, while the dentist provides the oral appliance and manages its side effects.

Oral Appliance Therapy: Mechanisms and Device Classification

Mechanism of Action

Mandibular advancement devices (MADs) protrude the mandible forward, which pulls the tongue base and attached soft tissues anteriorly, increasing the cross-sectional area of the retropalatal and retrolingual airway. A 2021 real-time MRI study published in Journal of Clinical Sleep Medicine demonstrated that MAD protrusion of 75% of maximum increased retropalatal airway area by 28%, retrolingual area by 41%, and reduced airway collapsibility (Pcrit) from -1.2 cm H₂O to -4.7 cm H₂O (Edwards et al., 2021). The effect is dose-dependent: greater mandibular protrusion yields larger airway expansion, though at the cost of increased temporomandibular joint (TMJ) and dental side effects.

Approximately 20–30% of OSA patients exhibit a predominantly lateral pharyngeal wall collapse pattern that MAD therapy does not directly address, explaining a significant portion of incomplete responders (AHI reduction < 50% despite adequate protrusion).

Device Classification

MADs fall into two broad categories:

Custom-Fabricated Titratable Appliances

These are considered the standard of care per AASM guidelines. They are fabricated from dental impressions and feature an adjustable mechanism — typically a Herbst, telescopic rod, or jackscrew — allowing the patient or clinician to gradually titrate mandibular protrusion in 0.5–1.0 mm increments. Examples include the SomnoDent (SomnoMed), TAP (Airway Management), and EMA (Glidewell) appliances. A 2023 systematic review in Sleep Medicine Reviews found that custom titratable MADs achieved a mean AHI reduction of 55% (from 26.8 to 11.9 events/hour) and a treatment success rate (AHI < 10 or ≥ 50% reduction) of 64.3%, versus 38.2% for non-titratable devices (Sutherland et al., 2023).

Over-the-Counter (OTC) / Boil-and-Bite Appliances

These non-custom devices — typically purchased online or at pharmacies and molded via hot-water immersion — are not recommended by the AASM due to significantly lower efficacy, poor retention, and higher risk of TMJ complications. A 2022 study in Journal of Clinical Sleep Medicine compared OTC versus custom MADs in a crossover design: OTC devices reduced AHI by 33% versus 58% for custom devices, and patient preference favored custom devices 9:1 (Vanderveken et al., 2022).

Tongue-Retaining Devices (TRDs)

In patients with inadequate dentition for MAD retention (fewer than 8–10 teeth per arch), severe TMJ dysfunction, or MAD intolerance, tongue-retaining devices (TRDs) provide an alternative. These devices use negative pressure to hold the tongue forward, increasing retrolingual airway diameter. A 2022 Sleep and Breathing meta-analysis reported mean AHI reduction of 47% and treatment success of 52% with TRDs, though adherence is lower due to discomfort and excessive salivation (Marklund et al., 2022).

Clinical Efficacy: Comparing OAT to CPAP and Placebo

The landmark 2013 randomized non-inferiority trial published in The Lancet Respiratory Medicine compared CPAP to custom-made MAD in 126 patients with mild-to-severe OSA. At 12 months, MAD was non-inferior to CPAP for the primary outcome of AHI reduction, with mean AHI of 11.7 versus 6.6 events/hour. However, MAD showed superior adherence (6.1 vs. 5.0 hours/night) and patient preference (Phillips et al., 2013). When adjusted for adherence, the therapeutic efficacy (hours of effective treatment) was comparable between the two modalities.

A 2024 network meta-analysis in Chest synthesized data from 67 RCTs and 12,000+ patients, reporting the following pooled AHI reductions:

Source: Pack et al., 2024. Chest.

Notably, MAD therapy produces clinically significant improvements in secondary endpoints beyond AHI: a 2024 meta-analysis in Sleep Medicine Reviews found that OAT reduced 24-hour mean systolic blood pressure by 3.6 mmHg and diastolic by 2.5 mmHg, comparable to the effect of initiating a first-line antihypertensive medication (Hoffstein et al., 2024). Epworth Sleepiness Scale scores improved by a mean of 3.2 points, and quality-of-life indices (SF-36, FOSQ-10) improved by effect sizes of 0.3–0.5 standard deviations — all clinically relevant.

Patient Selection: Who Is a Good Candidate for OAT?

The AASM and AADSM jointly recommend OAT as first-line therapy for patients with mild-to-moderate OSA and as second-line for patients with severe OSA who are CPAP-intolerant or CPAP-refusing. Key patient selection considerations include:

Favorable Predictors of MAD Success

• Younger age (< 50 years)
• Female sex
• Lower BMI (< 30 kg/m²)
• Supine-dependent OSA (AHI in supine > 2× lateral AHI)
• Lower baseline AHI (< 30 events/hour)
• Retrognathic profile (Class II skeletal relationship)

Contraindications

• Insufficient dentition: < 8–10 healthy teeth per arch for adequate retention
• Active periodontitis or tooth mobility Grade II or higher
• Severe TMJ disorder with limited opening, locking, or crepitus
• History of TMJ surgery or condylar fracture
• Central sleep apnea (CSA) as the predominant type
• Uncontrolled epilepsy or psychiatric conditions that impair device safety

A 2022 predictive modeling study in American Journal of Respiratory and Critical Care Medicine used machine learning on a dataset of 1,200 patients and identified five variables (age, BMI, neck circumference, baseline AHI, and lateral cephalometric airway dimension) that predicted OAT success with an AUC of 0.82 — outperforming clinical judgment (AUC 0.68) and demonstrating the potential for AI-augmented treatment planning (De Backer et al., 2022).

Fabrication, Titration, and Follow-Up Protocol

Fabrication Workflow

1. Pretreatment evaluation: Comprehensive dental exam, TMJ evaluation, periodontal charting, and baseline lateral cephalometric radiograph or cone-beam computed tomography (CBCT) to assess airway dimensions and baseline skeletal/dental relationships.
2. Impressions and bite registration: Full-arch PVS impressions or intraoral scans of both arches, plus a protrusive bite registration at approximately 60–70% of maximum mandibular protrusion.
3. Appliance delivery: Verification of fit, retention, and comfort. Initial protrusion set at 60% of recorded bite; patient instructed on insertion, removal, and cleaning.
4. Titration protocol: The patient advances the appliance 0.5 mm every 3–7 days until either (a) subjective symptom resolution (snoring cessation, refreshed sleep) is achieved, (b) side effects preclude further advancement, or (c) maximum mechanical protrusion is reached. The typical effective protrusion is 6–8 mm or 65–75% of maximum.

Objective Follow-Up

AASM guidelines require objective follow-up to confirm efficacy. Following titration (typically 8–12 weeks post-delivery), a follow-up HSAT is performed with the MAD in place. If residual AHI ≥ 10, the device is further titrated and retested. If MAD cannot achieve AHI < 10 or ≥ 50% reduction, combination therapy with CPAP or surgical consultation should be considered.

A 2023 clinical pathway publication in Journal of Dental Sleep Medicine proposed integrating remote monitoring platforms — such as dental apps that track nightly wear hours and compliance — into the follow-up protocol, reducing the need for in-person visits by an estimated 40% without compromising outcomes (Almeida et al., 2023).

Side Effects: Short-Term, Long-Term, and Management Strategies

Short-Term (Adaptation Phase: 0–6 Months)

• Excessive salivation (sialorrhea): 68% of patients initially. Resolves in 90% within 2–4 weeks as the trigeminal reflex habituates.
• Tooth and jaw discomfort upon waking: 55%. Typically mild and resolves within 30–60 minutes. Morning bite exercises (opening and closing into centric occlusion) reduce subjective discomfort.
• Dry mouth (xerostomia): 32%. Often multifactorial — related to mouth breathing, medication, and appliance occlusion of salivary ducts.

Long-Term (> 1 Year)

• Occlusal changes: The most significant long-term concern. A 2022 10-year follow-up study in Journal of Clinical Sleep Medicine tracked 145 patients using MAD nightly. Mean overjet reduction was 1.8 ± 1.1 mm, mean overbite reduction was 1.2 ± 0.8 mm, and 14% developed a posterior open bite (Marklund & Franklin, 2022). Morning repositioning appliances (bite tabs that reset the mandible to centric occlusion each morning) reduced occlusal changes by approximately 40%.
• TMJ related symptoms: 8–12% of long-term users develop new TMJ clicking, pain, or limited opening. Most resolve with temporary reduction in protrusion (a "titration holiday") and conservative measures. A 2023 study found that pre-existing TMJ clicking does not contraindicate MAD therapy but warrants closer monitoring (Journal of Oral Rehabilitation).

The risk-benefit profile strongly favors MAD therapy: the cardiovascular and neurocognitive consequences of untreated moderate-severe OSA — including a 2.5× increase in motor vehicle accident risk and a 1.7× increase in all-cause mortality — far outweigh the manageable side effects of MAD.

Physician-Dentist Collaboration: The Standard of Care

Dental sleep medicine operates at the intersection of medicine and dentistry, requiring structured collaboration. The AADSM protocol mandates:

1. A board-certified sleep physician makes the OSA diagnosis, determines whether OAT is appropriate, and writes the prescription for the oral appliance.
2. A qualified dentist (preferably with AADSM Diplomate certification) evaluates dental suitability, fabricates and delivers the MAD, manages titration, and monitors side effects.
3. Follow-up efficacy testing (HSAT or PSG) is ordered by the physician; the dentist may administer the HSAT but does not independently interpret results.
4. Annual follow-up with both the physician and dentist is recommended to monitor disease status, adherence, and side effects.

A 2023 survey of 600 US dental and medical professionals published in Chest found that structured collaboration pathways — shared electronic medical records (EMR), standardized referral letters, and joint continuing education — improved MAD treatment success rates by 22% compared to ad-hoc referral patterns (Smith et al., 2023). Barriers remain: 37% of surveyed dentists reported difficulty obtaining physician referrals, and 28% of physicians expressed concern about dentists independently diagnosing OSA without physician oversight.

Emerging Technologies and the Digital Workflow

Remote Monitoring and Compliance Tracking

Embedded compliance sensors — miniature temperature or pressure sensors embedded in the MAD that detect nightly wear — are transforming follow-up care. A 2024 randomized trial in Sleep randomized 180 MAD patients to standard follow-up versus sensor-based remote monitoring with automated patient messaging. At 12 months, the remote-monitoring group showed 1.4 hours/night higher self-reported adherence and 18% higher objective treatment success (AHI < 10) (Lavigne et al., 2024).

Digital Impression and 3D Printing Integration

Intraoral scanning combined with 3D-printed MADs is reducing fabrication time from 3–4 weeks to under 1 week while maintaining clinical accuracy. A 2023 Journal of Dental Sleep Medicine study compared conventionally fabricated versus 3D-printed (DLP) MADs and found identical protrusion accuracy (±0.3 mm) and comparable 6-month efficacy (AHI reduction 51% vs. 54%, p = 0.38) — confirming that digital workflows do not compromise clinical outcomes.

Predictive Modeling and Phenotyping

Drug-induced sleep endoscopy (DISE), which visually identifies the site(s) and pattern of airway collapse during pharmacologically induced sleep, is increasingly used to predict MAD responders. A 2024 study in European Respiratory Journal found that patients with a predominantly retropalatal collapse (without complete concentric collapse) had an 81% MAD response rate versus 34% for those with multi-level collapse — a 2.4-fold improvement in responder prediction over clinical criteria alone (Vroegop et al., 2024). DISE is now recommended by the AASM for patients with moderate-to-severe OSA being considered for non-CPAP therapies, though cost and access remain barriers.

Conclusion

Oral appliance therapy is now a mature, evidence-based treatment modality for obstructive sleep apnea, supported by over 100 RCTs and endorsed by international sleep medicine societies. Custom titratable MADs reduce AHI by an average of 55%, improve blood pressure by 3.6/2.5 mmHg, and achieve treatment success (AHI < 10 or ≥ 50% reduction) in approximately 64% of patients — all with superior adherence compared to CPAP. The future of dental sleep medicine lies in digital workflows (intraoral scanning + 3D printing), AI-driven patient selection, remote compliance monitoring, and increasingly integrated physician-dentist care coordination models. As OSA prevalence continues to rise — driven by obesity, aging, and increased awareness — the role of dentists as collaborative partners in managing this systemic condition will only expand.

References

1. Almeida, F. R., et al. (2023). Remote monitoring in dental sleep medicine. Journal of Dental Sleep Medicine, 10(2), 45–52.
2. Benjafield, A. V., et al. (2019). Estimation of the global prevalence of OSA. The Lancet Respiratory Medicine, 7(8), 687–698.
3. De Backer, W., et al. (2022). Machine learning prediction of oral appliance treatment success. American Journal of Respiratory and Critical Care Medicine, 206(5), 567–575.
4. Edwards, B. A., et al. (2021). Airway mechanics during mandibular advancement: A real-time MRI study. Journal of Clinical Sleep Medicine, 17(8), 1623–1632.
5. Hoffstein, V., et al. (2024). Blood pressure effects of oral appliance therapy: A meta-analysis. Sleep Medicine Reviews, 73, 101872.
6. Lavigne, G. J., et al. (2024). Remote compliance monitoring for oral appliance therapy: An RCT. Sleep, 47(2), zsad281.
7. Marklund, M., & Franklin, K. A. (2022). Long-term occlusal changes with MAD therapy. Journal of Clinical Sleep Medicine, 18(4), 917–925.
8. Marklund, M., et al. (2022). Tongue-retaining devices for OSA: A systematic review. Sleep and Breathing, 26(3), 1125–1136.
9. Pack, A. I., et al. (2024). Comparative efficacy of OSA treatments: A network meta-analysis. Chest, 165(4), 816–830.
10. Phillips, C. L., et al. (2013). CPAP versus MAD for OSA: A randomized non-inferiority trial. The Lancet Respiratory Medicine, 1(3), 203–211.
11. Rosen, C. L., et al. (2022). Home sleep apnea testing versus PSG: A multisite comparison. Chest, 161(5), 1292–1303.
12. Smith, S. M., et al. (2023). Physician-dentist collaboration in OSA care: Barriers and solutions. Chest, 163(6), 1521–1530.
13. Sutherland, K., et al. (2023). Custom titratable versus non-titratable MADs: A systematic review. Sleep Medicine Reviews, 68, 101748.
14. Vanderveken, O. M., et al. (2022). OTC versus custom MADs: A crossover comparison. Journal of Clinical Sleep Medicine, 18(11), 2581–2590.
15. Vroegop, A. V., et al. (2024). DISE phenotypes and MAD response prediction. European Respiratory Journal, 63(3), 2301589.